Internal tandem duplication (ITD) mutation in Fms-like tyrosine kinase 3 gene (FLT3/ITD) represents an unfavorable genetic change in acute myeloid leukemia (AML) and is associated with poor prognosis.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
In the Blood Cancer Journal study, blocking this protein treats a specific form of AML called FLT3-ITD AML that develops directly—without an MPN developing first. This type of AML can be treated ...
Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...
为解决 FLT3-ITD AML 患者治疗效果不佳及耐药难题，上海临港实验室的研究人员开展关于 IHCH9033 与 FLT3 抑制剂联合治疗的研究，发现二者协同增效且能克服耐药。推荐科研读者阅读，以了解该领域 ...
Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...
今日（1月18日），中国国家药监局药品审评中心（CDE）官网最新公示，第一三共（Daiichi Sankyo）申报的5.1类新药盐酸奎扎替尼片上市申请获得受理。公开资料显示，这是一款FLT3抑制剂Vanflyta（quizartinib），已经于2023年7月获美国FDA批准治疗带有FLT3-ITD突变阳性的新确诊急性髓系白血病（AML）成人患者，它用于AML患者三个治疗阶段——诱导、巩固和维持治 ...
NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance therapy for treating newly diagnosed FLT3-ITD-positive AML, an indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback